A Phase ???, Randomized, Double-Blinded Study Evaluating the Safety and Efficacy of Combination Treatment of Motixafortide and G-CSF as Compared to Placebo and G-CSF for the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Subjects With Multiple Myeloma
Latest Information Update: 19 Dec 2025
At a glance
- Drugs Motixafortide (Primary)
- Indications Multiple myeloma
- Focus Registrational; Therapeutic Use
- Sponsors Guangzhou Gloria Biosciences
Most Recent Events
- 16 Dec 2025 Planned End Date changed from 31 Dec 2026 to 31 May 2027.
- 16 Dec 2025 Planned primary completion date changed from 31 Aug 2026 to 31 Dec 2026.
- 16 Dec 2025 Status changed from not yet recruiting to recruiting.